基于tepotinib和omeprazole组合治疗的KRAS突变非小细胞肺癌 (NSCLC) 疗法
Rafael Rosell1,2,3, Eloisa Jantus-Lewintre4,5,6,7,8, Peng Cao9,10,11,12
1Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain. rrosell@iconcologia.net.
Cell communication and signaling : CCS
|June 12, 2024
概括
奥梅普拉和特波提尼布在治疗KRAS突变非小细胞肺癌 (NSCLC) 中表现有前途,包括耐药形式. 这种组合在体内证明了瘤回归,因此需要进一步研究NSCLC治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- KRAS突变非小细胞肺癌 (NSCLC) 对目前的治疗反应不佳.
- 过度表达c-MET受体氨酸激酶有助于KRAS突变NSCLC的瘤生长.
- 化疗,免疫疗法和KRAS-G12C抑制剂的有效性有限,需要新的治疗策略.
研究的目的:
- 评估梅醇与特波提尼布结合在KRAS突变NSCLC中的抗癌活性.
- 评估这种组合在耐药NSCLC细胞系中的疗效.
- 研究组合效应背后的分子机制,并与患者生存结果相关联.
主要方法:
- 在各种NSCLC细胞系中进行了细胞活力,协同作用和殖民地形成测试.
- 西部斑点分析和实时RT-qPCR用于评估蛋白质和mRNA表达.
- 在体内研究中使用了异种移植的小鼠模型,并分析了患者瘤样本的KRAS和METmRNA水平.
主要成果:
- 奥梅普拉加上特波提尼布在KRAS突变NSCLC细胞系中表现出显著的抗癌活性,包括对索托拉西布和特拉美提尼布耐药的细胞系.
- 该药物组合在异种移植小鼠模型中诱导了瘤生长回归.
- 在早期肺腺癌患者中,高KRAS和METmRNA表达水平与无复发生存率降低相关.
结论:
- 奥梅普拉 (一种V-ATPase抑制剂) 和特波提尼布 (一种MET抑制剂) 的组合显示了对KRAS突变NSCLC的治疗潜力.
- 这种组合对耐药NSCLC有效,包括对共价KRAS G12C抑制剂的耐药性.
- 对于KRAS突变NSCLC患者,需要对奥梅普拉和特波提尼布进行进一步的临床评估.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K